5 February 2021 (Friday) - Lymphomas and Lymphoid Neoplasia:

The American Society of Hematology sent an update on lymphomas and lymphoid neoplasia today:

Avelumab Shows Clinical Activity in Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma
Investigators also found that high PD-L1 expression correlated with achievement of complete response to avelumab in this patient population.
Guest Commentary: The Future of Chronic Graft-Versus-Host Disease
Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and challenges in the management of chronic graft-versus-host disease – the subject of a recent National Institutes of Health Consensus Conference.
FDA Accepts Investigational New Drug Application for PBCAR19B in Non-Hodgkin Lymphoma
The decision allows Precision BioSciences to initiate a phase I trial evaluating the safety and clinical activity of its CAR T-cell therapy in patients with relapsed or refractory NHL.


No comments:

Post a Comment